访问生物技术

2023年2月21日

2023年2月21日Hemab疗法,临床分期生物科技公司发展中第一个预防性治疗严重的出血和血栓性疾病,今天宣布关闭系列B超额认购1.35亿美元融资。访问生物技术引领一轮,新投资者的参与深度追踪资本,Avoro Ventures Invus,岩石泉资本和Maj投资股权,以及所有当前投资者Novo控股,RA Capital Management, HealthCap。“Hemab从根本上重塑缺医少药出血和血栓性疾病的治疗模式。这个融资将使我们进步临床项目第一预防性治疗Glanzmann血小板机能不全和血管性血友病,实现功能治疗病人的需要,“本尼索伦森说,医学博士,首席执行官& Hemab总统。“我们感激这健壮的辛迪加的投资者支持我们的方法利用先进技术进行验证和深入的生物学凝血克服几十年的科学停滞。“融资将支持Hemab科学和企业增长计划到2025年,包括完成的1/2期临床研究的领先候选人hmb - 001 Glanzmann血小板机能不全,起始的关键研究,开始和完成1/2期临床评估HMB-VWF血管性血友病,进化和未来管道按照公司战略guidance-targeting Hemab 1-2-5™开发5临床资产2025。“强大的投资者信心,这种情况下,一个更大的圆和超过2亿美元的需求证明Hemab的专业团队,他们验证科学方法,和机会带来期待已久的创新与严重的出血和血栓性疾病患者,”约翰·Maraganore说博士Hemab董事会主席。”成立投资者和公司的最大股东,我们兴奋地支持Hemab计划的下一阶段构建最终的凝血公司,与一个北欧基金会和全球足迹,“说Jørgen Søberg彼得森,医学博士,博士学位,MBA,新生的合伙人持有。Hemab还宣布丹贝克,医学博士,董事总经理访问,和Uya Chuluunbaatar,博士Avoro Ventures合伙人也将加入董事会。克里斯汀博罗夫斯基博士、副总裁访问将加入董事会观察员。 “We are thrilled to partner with Hemab’s exceptional leadership to advance a pipeline of transformative new medicines for areas of high unmet need in hemostatic disorders,” said Dr. Becker. About Hemab Therapeutics Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in the US and Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5TM, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and other serious disorders. Learn more at hemab.com . About HMB-001 HMB-001 is bispecific antibody that binds and stabilizes endogenous factor VIIa (FVIIa) with one antibody arm and TLT-1 on activated platelets with the other arm. This allows for accumulation of FVIIa in the body, recruitment of FVIIa directly to the surface of the activated platelets where it is known to facilitate clotting, and avoidance of clotting activity in the absence of tissue damage. HMB-001 was designed to be a first-in-class prophylactic treatment for Glanzmann Thrombasthenia with potential for other debilitating rare bleeding disorders. It entered Phase 1/2 clinical evaluation in late 2022, with initial data expected 2H 2023.